Navigation Links
Kensey Nash Announces the Closing on its Sale of the Endovascular Business to Spectranetics
Date:6/2/2008

EXTON, Pa., June 2 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) reported the closing of the previously announced sale of its endovascular business to Spectranetics Corporation (Nasdaq: SPNC) was completed on May 30, 2008. This transaction includes the sale of the ThromCat(TM), QuickCat(TM) and SafeCross(TM) products.

Joseph W. Kaufmann, President and CEO of Kensey Nash, commented, "As a result of the efforts of the Kensey Nash and Spectranectics transition teams we were able to complete the closing of this transaction in less than three weeks. We are very excited about the prospects of this strategic partnership, which provide the opportunity for substantial future growth. Our plans for the next generation products, combined with the larger and more established Spectranectics sales team, will place us in a position to achieve this growth opportunity with improved treatment options in the Thrombus and Chronic Total Occlusion markets," he concluded.

About Kensey Nash Corporation. Kensey Nash Corporation is a leading medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily in the sports medicine, spine, and endovascular markets. Many of the products are based on the Company's significant expertise in the design, development, manufacturing and processing of absorbable biomaterials, which has led to partnerships to commercialize technologies. Kensey Nash has also developed and commercialized a series of innovative endovascular products and recently announced the sale of this product line to Spectranetics, Inc. In conjunction with the sale transaction, the Company will continue to manufacture and develop these products for Spectranetics for a period of time. The Company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.

Cautionary Note for Forward-Looking Statements. This press release contains forward-looking statements that reflect the Company's current expectations about its prospects and opportunities, including the statement regarding anticipated growth of the products sold to Spectranetics. The Company has tried to identify these forward looking statements by using words such as "expect," "anticipate," "estimate," "plan," "will," "forecast," "believe," "guidance," "projection" or similar expressions, but these words are not the exclusive means for identifying such statements. The Company cautions that a number of risks, uncertainties, and other important factors could cause the Company's actual results to differ materially from those in the forward-looking statements including, without limitation, risks associated with the Company's continued research and development efforts with respect to the endovascular products (including the risk that those efforts will not be successful and that some or all of the associated milestone payments will not be received) and Spectranetics' success in selling the ThromCat and SafeCross products, as well as competition from other technologies. For a detailed discussion of factors that could affect the Company's future operating results, please see the Company's SEC filings, including the disclosure under "Risk Factors" in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference
2. Kensey Nash Announces $25 Million Stock Repurchase Program
3. Kensey Nash Reports Acceleration of Stock Awards Triggered by Shareholder Acquisition of Greater Than 20% of Outstanding Shares
4. Kensey Nash Reports First Quarter Fiscal Year 2008 Results
5. Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform
6. Kensey Nash to Present at the 19th Annual Piper Jaffray Health Care Conference
7. Kensey Nash Corporation Announces Its Second Quarter 2008 Earnings Release Date and Teleconference
8. Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million
9. Kensey Nash to Participate in the Sidoti Twelfth Annual New York Emerging Growth Institutional Investor Forum Conference
10. Kensey Nash Reports Third Quarter Record Revenue and Sales
11. Kensey Nash to Present at the Bank of America 2008 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... supplement development, announced it attended the January ECRM trade show to continue the marketing ... technologically advanced vitamin C supplement, known for providing 400 percent better absorption than traditional ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... ... wellness products to enhance people’s everyday lives, recently attended the January ECRM Trade ... , ATP Science is known for its large range of supplements that keep ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... "TransFlare 4K ... use inside of Final Cut Pro X," said Christina Austin - CEO of Pixel ... RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak transitions ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “The Angel”: ... Lord has set out for each of his children. “The Angel” is the creation ... of Music in New York City, and impassioned writer. , When asked of her ...
(Date:1/20/2017)... ... 2017 , ... D R Burton Healthcare Products LLC, makers ... in a study indicating superior performance against competitive products in secretion clearance. ... Positive Expiratory Pressure Devices During Simulated Breathing“ was published in the winter issue ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... InDex Pharmaceuticals Holding AB (publ) today announced ... of the European Crohn,s and Colitis Organisation (ECCO). The ECCO congress ... on inflammatory bowel disease (IBD). The congress is held in ... ... again having been selected to present data at the largest IBD ...
(Date:1/23/2017)... 23, 2017 Just two weeks remain until legal experts and ... in Central London to discuss the flow of ... the market, Parallel Trade 2017 . In the run ... attendees which is available to read in the event download centre ... Some of those ...
(Date:1/22/2017)... ABU DHABI , Saudi Arabia , January ... the US and UAE ... of the Future , at the World Economic Forum   ... future will be driven by big data and powered by artificial intelligence and ... of experts that discussed the ,Hospital of the Future, at the concluding day ...
Breaking Medicine Technology: